Novartis (NVS) presents new Pluvicto data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology, ESMO, Congress 2025. Pluvicto plus standard of care demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival, rPFS, reducing the risk of radiographic progression or death by 28% versus SoC alone in patients with prostate-specific membrane antigen+ metastatic hormone-sensitive prostate cancer. Results also show an early positive trend in overall survival, OS, in patients treated with Pluvicto plus SoC; follow-up will continue until data are mature. More patients achieved a complete response versus SoC alone and the overall response rate, ORR, was numerically higher in the Pluvicto plus SoC arm. Pluvicto delayed time to progression to metastatic castration-resistant prostate cancer. The rPFS benefit was consistent across pre-specified subgroups.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
- Novartis announces results from five-year analysis of NATALEE trial of Kisqali
- Novartis Scemblix receives positive CHMP opinion for Scemblix
- Novartis announces Phase III study of Fabhalta showed superiority to placebo
- Trump Weekly: Generics to be excluded from pharma tariff plan